Gout
📧 Sign up to get email alerts when something new happens for Gout.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-07-28FDA Approved: NAPROXEN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for Naproxen from Glenmark Pharmaceuticals to update the labeling for the generic product under the …
-
FDA approval · 2020-06-02FDA Approved: FEBUXOSTAT — Original Application (HEC Pharm USA Inc.)
The FDA approved the original application for febuxostat submitted by HEC Pharm USA Inc., authorizing a generic version of febuxostat. Febux…
-
FDA approval · 2020-03-30FDA Approved: COLCHICINE — Supplemental Application (Dr.Reddys Laboratories, Inc.)
FDA approved a supplemental application for Colchicine submitted by Dr. Reddy's Laboratories, Inc.
-
FDA approval · 2020-03-19FDA Approved: NAPROXEN — Supplemental Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's supplemental application for naproxen (generic) under ANDA075390. This action constitutes a suppleme…
-
FDA approval · 2019-12-30FDA Approved: FEBUXOSTAT — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original Abbreviated New Drug Application for febuxostat (generic) by Novadoz Pharmaceuticals LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-12-30FDA Approved: FEBUXOSTAT — Original Application (Tris Pharma Inc)
The FDA approved an original application for febuxostat from Tris Pharma Inc, representing a generic product. The approval covers febuxostat…
-
FDA approval · 2019-11-22FDA Approved: NAPROXEN SODIUM — Supplemental Application (CVS)
FDA approved a supplemental application for Naproxen Sodium from CVS under ANDA 091353, resulting in updated approval for the product.
-
FDA approval · 2019-11-15FDA Approved: NAPROXEN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for a generic Naproxen product from Hikma Pharmaceuticals USA Inc. This action expands access to…
-
FDA approval · 2019-11-14FDA Approved: COLCHICINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for COLCHICINE from Zydus Lifesciences Limited. This indicates a supplemental approval for this gene…
-
FDA approval · 2019-10-26FDA Approved: NAPROXEN SODIUM — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for Naproxen Sodium from Bionpharma Inc., resulting in an approved modification to the product’s lab…
-
FDA approval · 2019-10-15FDA Approved: FEBUXOSTAT — Original Application (Hikma Pharmaceuticals USA Inc)
FDA approved Hikma Pharmaceuticals USA Inc for a generic febuxostat via an original ANDA (ANDA205414). This approval expands access to urate…
-
FDA approval · 2019-09-16FDA Approved: COLCHICINE — Original Application (Mylan Pharmaceuticals Inc.)
The FDA approved a generic colchicine product from Mylan Pharmaceuticals Inc. under an original ANDA (ANDA209470).
-
FDA approval · 2019-09-06FDA Approved: COLCHICINE — Original Application (Dr.Reddys Laboratories, Inc.)
FDA approves Dr. Reddy's Laboratories' original ANDA for colchicine, enabling sale of a generic colchicine product.
-
FDA approval · 2019-07-01FDA Approved: FEBUXOSTAT — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' original application for febuxostat (generic febuxostat). This ANDA approval provides a generic …
-
FDA approval · 2019-07-01FDA Approved: FEBUXOSTAT — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original ANDA for febuxostat, a generic version of the gout and hyperuricemia therapy.
-
FDA approval · 2019-04-23FDA Approved: ALLOPURINOL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Allopurinol from Mylan Pharmaceuticals Inc., representing a supplemental approval for the produc…
-
FDA approval · 2019-03-19FDA Approved: ALLOPURINOL — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for allopurinol (generic) submitted by Chartwell RX, LLC.
-
FDA approval · 2019-03-12FDA Approved: ALLOPURINOL — Original Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved Unichem Pharmaceuticals (USA), Inc.'s original application for Allopurinol, a generic drug used to treat gout and hyperuric…
-
FDA approval · 2019-02-21FDA Approved: ULORIC — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ULORIC (febuxostat) from Takeda Pharmaceuticals America, Inc., reflecting an additional regulato…
-
FDA approval · 2019-02-19FDA Approved: COLCHICINE — Original Application (Zydus Lifesciences Limited)
FDA approved an original application for Colchicine from Zydus Lifesciences Limited, enabling a generic version of the drug to reach the mar…
-
FDA approval · 2019-02-08FDA Approved: COLCHICINE — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories, LLC's original ANDA application for Colchicine, making a generic colchicine product available in the U.S.
-
FDA approval · 2019-01-30FDA Approved: GLOPERBA — Original Application (Scilex Pharmaceuticals Inc.)
The FDA approved GLOPERBA, a colchicine oral solution from Scilex, marking the original application approval for this colchicine product.
-
FDA approval · 2018-12-03FDA Approved: ALLOPURINOL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Allopurinol filed by Rising Pharma Holdings, Inc.
-
FDA approval · 2018-11-29FDA Approved: NAPROXEN SODIUM — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for Naproxen Sodium from Bionpharma Inc., confirming regulatory clearance for an updated product-rel…
-
FDA approval · 2018-11-29FDA Approved: COLCHICINE — Original Application (Par Health USA, LLC)
The FDA approved an original ANDA for colchicine from Par Health USA, LLC, enabling the marketing of a generic colchicine product. This repr…